Industry news, page-2057

in reply to the question about the sentiment of Cu6 holders. As one these are my thoughts....

I've studied Cu6 very closely over the past 6 months. There is still plenty of upside with their diagnostics being touted as best in class (just been fast tracked for FDA approval) and the therapeutic pipeline showing unbelievable results in early trials for patients where all lines of current therapy have been exhausted. I'm in that for the long haul and can absolutely see the SP getting to $14.00. I'd have to do my research on RAC but there is a distinct air of something big brewing at Clarity in the not too distant future. There would have to be something pretty special here to pull funds out of there and into RAC.(Came to this forum to start my research as a matter of fact, not to swap positions but to add to my portfolio.)